A Perfectly Executed Fianchetto

I was 12 years old, sitting across from this grizzled chess master in Washington Square Park – one of those guys who could probably beat you blindfolded while eating a hot dog. He demolished my carefully planned opening in about six moves.

While I was proudly moving my knight to what I thought was a brilliant attacking position, he was already three moves into a combination that would leave my king exposed.

“Kid,” he said, tapping the board, “you’re looking at the trees, but I’m seeing the whole damn forest.”

Twenty-three years later, watching AbbVie (ABBV) navigate the pharmaceutical landscape, I finally get what that old-timer meant. While everyone else is fixated on quarterly earnings and guidance raises, AbbVie is playing an entirely different game.

The stock just popped 11.4% in August after six months of looking like yesterday’s leftovers, and suddenly everyone’s acting surprised. Here’s the thing, though – if you’d been paying attention to the signals, this wasn’t exactly a shock.

Let’s talk about what really moved the needle here, because it wasn’t just the obvious stuff everyone’s parroting about earnings beats.

Sure, AbbVie crushed their Q2 numbers with $2.97 adjusted EPS versus the $2.84-2.88 guidance range – their fourth consecutive earnings surprise, which is starting to look less like luck and more like a pattern.

But this is what really caught my attention: they’ve raised guidance five times since March. Five times.

The EU-US pharmaceutical tariff settlement at 15% instead of the nuclear option of 250% was like watching someone defuse a bomb with three seconds left on the timer.

AbbVie manufactures across Germany, Ireland, and Italy, so this wasn’t just good news. It was “dodge a massive bullet” news.

They’d already started planning $10 billion in US manufacturing expansion as insurance, including a $195 million Illinois facility. Now they can probably take a more measured approach instead of panic-building factories.

On top of these, Rinvoq just nailed its alopecia trials – 55% of severe patients getting 30mg doses achieved 80% scalp coverage in 24 weeks.

Now, before you shrug and move on, consider this: there are 7 million Americans dealing with alopecia, and Rinvoq already pulled in 13% of AbbVie’s total revenue last quarter with a 41.8% year-over-year increase.

We’re not talking about a nice-to-have drug expansion here. We’re looking at a potential blockbuster indication for an already successful treatment.

The immunology segment brings in half their revenue, and they just found another way to make it bigger.

Then there’s the Gilgamesh acquisition – $1.2 billion for psychedelic depression treatments.

On paper, it’s 28% of their 2024 net earnings, which sounds hefty until you realize this is AbbVie building out their neuroscience portfolio, which already represents 17.4% of revenues.

That means this move wasn’t really about just buying a company. Instead, they’re buying into a therapeutic area that’s about to explode. The timing here is fantastic; getting into psychedelics before the regulatory floodgates fully open is like buying Amazon (AMZN) stock in 1997.

Now, here’s where the rubber meets the road, and why I respect companies like AbbVie even when the numbers make me wince a little.

At current levels, we’re looking at an 18.36x forward P/E if that acquisition hits earnings this year – and that’s assuming the worst-case scenario of paying the full $1.2 billion upfront.

Compare that to their five-year average of 12.5x, and yeah, the stock looks stretched. By about 28%, if we’re being honest.

But this is where being a chess player helps me think differently. The 2026 forward P/E sits at 14.6x based on analyst estimates, and by 2028, we’re talking about fair valuation territory with actual upside potential.

AbbVie isn’t simply riding the Humira wave into the sunset. They’re actually methodically building the next generation of revenue streams while everyone else is still trying to figure out what post-Humira looks like.

That old chess master in Washington Square taught me something that day that I didn’t fully appreciate until decades later: the best players aren’t just reacting to what’s happening on the board right now. They’re setting up moves that won’t pay off for another five or six turns.

AbbVie’s building its psychedelic portfolio while regulators are still figuring out the rules. They’re expanding Rinvoq into new indications while competitors are still trying to catch up to their current success.

And they’re doing all of this while maintaining a dividend that’s been growing for over a decade.

Sometimes the most expensive-looking investment is actually the bargain, because everyone else is still staring at the knight while the real game is happening three moves ahead.

That grizzled master would’ve loved this stock.